Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

skip to content

Evelo Biosciences Announces Participation at Guggenheim Microbiome Day

Cambridge, Mass. - April 14, 2016

CAMBRIDGE, Mass., April 14, 2016/PRNewswire/– Evelo Biosciences, the pioneer of Oncobiotic™ Therapies, microbiome-based therapeutics for cancer, today announced it will participate in the Guggenheim Securities Microbiome Day on April 21, 2016 in New York, NY.

Simba Gill, Ph.D., CEO of Evelo, will participate in a panel entitled Next Frontier: Other Diseases That May Be Targets of Microbiome Manipulation at 2:00 pm EST.

The conference will feature discussions on the bourgeoning microbiome field, with key thought leaders, investors and members of senior management from leading microbiome companies.

About Evelo Biosciences

Evelo Biosciences is dedicated to transforming cancer therapy through a deep understanding of the mechanisms and biology of the cancer microbiome. Evelo is developing Oncobiotic™ therapies, derived from its Bacterial Immune Activator (BIA™) and Cancer Associated Bacteria (CAB) proprietary platforms, designed to disrupt the tumor microenvironment, activate the immune system against tumors and interfere with tumor metabolism. Founded by Flagship VentureLabs® in 2015, Evelo is the world’s first microbiome company focused on the treatment of cancer. For more information, please visit

Media Contact:

Evelo Biosciences

Stefan Riley

(617) 461-2442 (cell)